Industry News

• U.S. to provide antiviral medication to Latin America and the Caribbean for H1N1 influenza  HHS Secretary Kathleen Sebelius announced that the United States will provide 420,000 treatment courses of Tamiflu (Oseltamavir) to the Pan-American Health Organization (PAHO) to fight the novel H1N1 influenza in Latin America and the Caribbean.
  Dept. of Health & Human Services July 02, 2009  
• FDA approves Multaq to treat heart rhythm disorder  The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders).
  FDA July 02, 2009  
• UNMC transplant experts write chapters in highly regarded book  When editors of a comprehensive reference book on stem cell transplantation needed experts to write chapters for the book, they turned to the University of Nebraska Medical Center. Four College of Medicine faculty oncologists and hematologists answered the call.
  University of Nebraska Medical Center July 02, 2009  
• Johnson & Johnson and Elan Corporation announce definitive agreement  Johnson & Johnson and Elan Corporation announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through a newly formed company.
  Johnson & Johnson July 02, 2009  
• Madison firm expands alliance with Roche  Cellular Dynamics International, a firm co-founded by stem cell pioneer and University of Wisconsin-Madison researcher James Thomson, is expanding a research and development agreement with Swiss pharmaceutical firm Roche.
  The Business Journal of Milwaukee July 01, 2009  David Schuyler
• Graceway Pharmaceuticals acquires early-stage dermatological molecules from Pfizer  Graceway Pharmaceuticals and Pfizer announced that they have entered into an Acquisition and License Agreement by which Graceway will acquire worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.
  Pfizer Inc. July 01, 2009  
• FDA: Boxed warning on serious mental health events to be required for Chantix and Zyban  The U.S. Food and Drug Administration announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion).
  FDA July 01, 2009  
• Ruth Macnamara appointed assistant dean of new UNMC College of Nursing Northern Division  Ruth (Pakieser) Macnamara, Ph.D., has been appointed assistant dean of the new University of Nebraska Medical Center College of Nursing Northern Division in Norfolk effective July 1. Dr. Macnamara is the founding and transitional dean.
  University of Nebraska Medical Center July 01, 2009  
• Pfizer updates CHANTIX (R) (varenicline) labeling in the United States  Pfizer announced that it has updated the U.S. product labeling for CHANTIX(R) (varenicline), a prescription aid to smoking cessation treatment, to communicate important safety information in a boxed warning as well as in revised warnings and precautions.
  Pfizer Inc. July 01, 2009  
• Pfizer launches medicine assistance program for newly unemployed  An assistance program offered by Pfizer that can help unemployed Americans continue receiving their prescription medicines. The program is fully operational July 1.
  Pfizer Inc. July 01, 2009  

   (next 10 articles)